CellChorus

CellChorus is a biotechnology company that specializes in dynamic single-cell analysis. Their proprietary Time-lapse Imaging Microscopy In Nanowell Grids (TIMING) platform enables researchers to visually evaluate and quantify how individual cells move, interact, kill, survive, and secrete biomolecules over time at single-cell resolution. The TIMING platform leverages artificial intelligence and neural network-based detection to identify the functional characteristics and performance of thousands of cells simultaneously. This technology provides comprehensive insights into cellular behavior, which can facilitate the development, manufacturing, and delivery of novel therapies, particularly in the fields of oncology, infectious diseases, and other disorders.

One of the key differentiators of CellChorus' approach is its ability to study the dynamic nature of cells and their interactions, as opposed to static analysis. By capturing live cell imaging data, the TIMING platform enables researchers to observe and understand the adaptive behaviors of cells in response to various stimuli or microenvironments. This capability is particularly valuable in the development of cell-based therapies, such as immunotherapies, where understanding the functional dynamics of immune cells is crucial.

The TIMING platform has been utilized in various research projects, with data from the platform featured in over 20 peer-reviewed publications across different therapeutic areas. In March 2022, CellChorus published data demonstrating the importance of T-cell immunity in SARS-CoV-2, showcasing the platform's versatility in studying cellular immune responses.

In June 2023, CellChorus was awarded a USD 2.3 million SBIR Fast-Track grant from the National Institute of General Medical Sciences to further develop and scale the TIMING platform. Additionally, in May 2024, the company received a USD 2.1 million SBIR Fast-Track grant from the National Center for Advancing Translational Sciences to advance the platform's capabilities.

Key customers and partnerships

CellChorus has established collaborations with various industry leaders, including top biopharmaceutical companies, promising venture-backed biotechnology firms, and leading non-profit research institutions. The company's platform has been utilized by these organizations for a wide range of applications, including research, preclinical development, clinical development, manufacturing, and the identification of biomarkers predictive of patient response.

In July 2022, CellChorus joined the NVIDIA Inception program, which aims to nurture startups revolutionizing industries with advancements in artificial intelligence and data sciences. This partnership provides CellChorus with access to cutting-edge technology, industry experts, and opportunities for collaboration with other AI-driven organizations, enabling the company to accelerate its growth and expand its capabilities.